Company Name: Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. The company develops therapeutics designed to treat rare diseases and has collaborations with several pharmaceutical companies. The company’s Glybera® is a gene therapy designed to treat lipoprotein lipase deficiency (LPLD) and has been approved in the European Union. The company’s pipeline includes treatment candidates for a variety of conditions including postherpetic neuralgia, dermatological disorders, cardiovascular disease, pain and Dravet Syndrome (DS).
Ticker Symbol: XENE (NASDAQ)
Company Website: www.xenon-pharma.com
Headquarters: Burnaby, BC Canada